Non-Pharmacological Interventions For Parkinson'S Disease Mild Cognitive Impairment: Future Directions For Research

Parkinson's disease-mild cognitive impairment (PD-MCI) currently represents a valid diagnostic clinical entity with potential interest for therapeutic purpose. MCI is present in approximately 25–30％ of non-demented patients with PD (Weintraub et al., 2018). Several risk factors are associated with Parkinson's disease dementia (PDD) occurrence, such as old age at onset, long disease duration, motor impair-ment and MCI (Nicoletti et al., 2019). Specifically, PD-MCI patients with a higher risk for conversion into PDD report specific neurocognitive deficits in semantic language, figure drawing/copying and visuospatial tasks (Vasconcellos et al., 2019). Thus, the implementation of strategies counteracting a more severe cognitive deterioration of PD-MCI patients is urgently required.